We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kind words were said about him and quite rightly so but I totally agree that this was unnecessary cost in the management structure that was inevitably going to get trimmed once Lyn had got his man Hayden in situ. Nick has a very strong organisational background and clearly a lot of valuable experience, having gone through his Linkedin profile, but I do still question whether his days could also be numbered. Time will tell.
Although it is never great to celebrate a person's departure from their job I think this is good news and inevitable. Since Hayden Jeffreys (Group Commercial Director) appointment there has been too much potential overlap with Chief Commercial Officer (Nick Claxton) and Chief Business Officer (Peter Collins) roles. So it is good to see that IR and the new CEO have understood this challenge. This should help the cost management efforts as well. His departure shouldn't affect any commercial regeneration post litigation release and is opportune in advance of the company relaunch which I would suggest will happen in the next 3 weeks in advance of the Half Year results.
Although these posts on ANGL and CPT are nice to see on other companies boards and I guess achieved their purpose in an effort to raise publicity to RNS issued about them we should also appreciate key differences in underlying technology. Neither of these products rely on NGS from my understanding. The Concepta product being a home test with an app and the Angle product trying a different test approach than Cell Free DNA hence not needing the IONA test of multi-parallel sequencing. This would be important from Illumina/TMO's perspective in buying in to any future product development. However let us see as its still early days for both of these companies which roughly are 5 years behind Premaitha / YourGene - and we LTHs all know what can happen in the interim. I also accept that Premaitha/YourGene could also find commercial partners to spread the costs of further commercialisation.
With a further 4 products at least planned in the next 2 years, and I suspect reproductive health announcement shortly, it should be interesting to see the revised strategic direction. Hopefully with AR (and Steve Myers) paying 10p last week on further placing subscriptions we should start seeing some news flow alongside a company relaunch which would have to happen in the next 3 weeks.
To stay within the present theme I would like to add and emphasise the importance of the broader scope we have recently acquired. Certainly an important point raised Hertstrada74, our outstretch incorporating both TF and Illumina has now become an attractive opportunity for any company such as CPT to be drawn into and promote their wares. AGL gave food for thought in there recent RNS, "ANGLE is in discussions with interested parties with a view to securing one or more corporate partners for NIPT commercialisation so as not to divert existing resources from our key established cancer projects.".
Although two or three years away from commercial acceptability, their product would be an added bonus for Premaitha to offer a next stage development product. In tern, Premaitha would be an attractive platform from which to launch such a product to commercialisation in quick time.
Concepta has a CE-IVD their product myLotus and allows women the ability to self-test to identify their optimal fertile days whereas (now) YourGene Health focuses on molecular diagnostics e.g. chromosol problems. So different parts of reproductive health. So for example part of the reproductive health products that the company will release is Pre-implantation genetic screening (PGS) which is a technique for testing whether embryos have any problems with their chromosomes, which is thought to be the most common reason why IVF treatment fails.
Could happen however good plug for CPT regardless.
The collaboration I would like to see is more strategic opportunities with Illumina. So for example from 2019 onward, in the UK the National Health Service will offer "all seriously ill children" whole-genome sequencing as part of their standard care, as well as to adults with certain rare diseases or "hard-to-treat" illnesses, the UK government said. In addition, patients will be asked to give consent for their genomic data to be analysed in an effort to develop new tests and treatments for cancer and rare diseases. The plan is for the NHS Genomic Medicine Service to expand on existing projects, such as the 100,000 Genomics Project and sequence 1 million whole genomics within five years.
So although Illumina have been the villain on this BB for the last 4 years, now as a strategic partner and YourGene Health now as a PPA licensee there could be other strategic opportunities before the Illumina CE-IVD is produced. However let's see as I suspect that more details of the strategic revision will be released in the next month.
Anyone else in CPT. I took a position there the other day. Similar products to us, fertility kits, would be great if they collaborated
creeping up slowly patience is key.
With the BoD subscribing to 8.5m shares and Steve Myers Holding RNS showing a delta of 3.5m shares from his last threshold I would have imagined that as the placing raised £3.5m that some other IIs would have had to be part of the delta 35m shares. However to be honest it is fairly opaque.
It all depends if you think relaunch will happen by 3/12 or not.
If you believed that the BoD would want to deliver by the Half Year Results which are roughly 4 weeks away you would imagine that the next 3 weeks or so will be quite busy behind the scenes. I suspect that at the very least the Company Name change and TDIM will be changed by the Half Year results. So then that leaves whether they will be able to negotiate the TMO warrants conversion and broker forecast change by then. The delta would require to e driven by contract awards as well. Both have been set as aspirations for the BoD but we will have to see whether they can meet the Half Year Results statement and you would have imagined this would have to be at least an internal target for some milestones discussed.
Steve Myers ...rest of bod ...maune the money is going straight to working capital. Wouldnt the ii.s stump up the cash ...it was a paltry amount in tge grand scheme of things.Myers cant really chip in knowing there.s something biggish around the corner. All a bit odd.
snooze..
no commercial partner, no fda approval, 17 test patients, years away from phase 3 trials and commercialisation and trawling through other BBs to get PIs
there must have been some reason that steve myers (plus ar) paid 17% premium on sp last week on sp
Hopefully this month will see relaunch and recovery post year highs.
snooze..
no commercial partner, no fda approval, 17 test patients, years away from phase 3 trials and commercialisation and trawling through other BBs to get PIs
there must have been some reason that steve myers (plus ar) paid 17% premium on sp last week on sp
Hopefully this month will see relaunch and recovery post year highs.
This was a small-scale pilot study and, whilst highly encouraging, substantial further work will be necessary to develop an effective NIPT test. Note the word "substantial"..
However, current NIPT has two key limitations. First and foremost, NIPT is currently based on analysis of cell-free fetal DNA (fragments of dead fetal cells) which is limited to testing for chromosomal disorders that are caused by the presence of an extra or missing copy (aneuploidy) of a chromosome. These include trisomy 21 (Down's syndrome) and a small number of other very rare conditions. The second limitation is a barrier to entry for companies offering NIPT as current methods are based on next generation sequencing analysis of cell-free DNA and the intellectual property is tightly held by a few large corporates.
Very interesting sell Nipt buy Angle
I didn’t realise he had spent time with Illumina but that very interesting. He’s definetely the right calibre of person to be representing them at this sort of event and hopefully helping bag some new business.
Cheers for this. The reason this is also of interest is that the presenter Robert Henke who will be presenting for Premaitha originally comes from Illumina (where he was Director of Clinical Sales) and beforehand Affymetrix.
Changing of company's TDIM will need some sort of publicity (more than the usual TW bearcast I suppose) and we may see some the news that we had hoped to come by time of the AGM to come with this co-ordinated relaunch. Hopefully the coming week will confirm the date of the formal name change. I think that the market has yet to appreciate that if one steps back from some of the individual set-backs one can see that the BoD through the placing, Company Name change, warrants conversion/debt relief, new products etc. have a chain of events to relaunch the Company - hopefully in the right direction this time - let's hope.
Premaitha is attending the Taiwan Healthcare+ Expo, 29 November-2 December 2018 and Robert Henke (Area Director, Asia Pacific) is presenting on behalf Yourgene Health, under the ‘BioInnovation Stadium: From Entrepreneurship to Ecosystem’ umbrella of presenters, along with the likes of Johnson & Johnson. It’s got 1400 booths and 400 exhibitors over the 3 days and we now know that the new name will be in full use by this time, so an excellent time to pump the new brand and the new strategy, once that is finalised by Lyn and the rest of the Board.
Imv Thermo were probably instrumental in not settling and going to court. They owe us so much that they should write the debt off completely. Never going to happen of course, but the sentiments hold.
Agreed. I can play Cassandra, notaflipper does a great Mr Micawber and your Polonius is superb, but at the end of the day it’s just words and opinions. We are in a better position than we were but it’s simple that the Board just need to deliver on the potential. I still suspect that the position with regard to TF is more complex than some believe. I mean after all the support they have given us having basically saved us from extinction they are not going to be happy with a position whereby we are selling Illumina and TF products outside the PPA territories. Our indebtedness to them gives them a lot of control and they are not going to give that up by offering gifts such as debt write-offs without something significant in return. It would be naive to think otherwise. Time will tell but I am optimistic. I just lack confidence in the Board.
I would have to agree that the company is in a much better position.
Although we were told more would come shortly at the 16th Oct Investor on reproductive health we also know via the product route map that by 2020-21 (when the new Illumina CE-IVD will also be launched) the product range will also include by then the following:
a) Pre-implantation genetic screening (PGS) – a technique for testing whether embryos have any problems with their chromosomes, which is thought to be the most common reason why IVF treatment fails.
b) Rhesus disease screens in which DNA from the unborn baby, found in the mother's blood, can be tested to determine if the foetus is at risk from the mother’s antibodies (when the mother’s blood is rhesus-negative and the foetus is rhesus-positive), which can destroy the red blood cells, causing jaundice, anaemia, miscarriage or stillbirth.
c) BRAC1 screens to pre-determine if a foetus is at risk of inheriting an altered (mutated) BRCA1 gene, which has been shown to increase a woman's chance of developing breast cancer and ovarian cancer.
Although the new Illumina test will only come in 2020, Premaitha has ALREADY taken a licence under Illumina’s patent pool agreement (PPA). This is important as PPA patents were pending in Brazil and India so clears. It allows Premaitha to also offer Illumina NGS lab services in interim to access the 80% of market on Illumina NGS. The Illumina CE-IVD would however I think allow Premaitha to expand more freely into US, Mexico and Australia. NOW through the settlement, in any non-PPA licensed territory (majority of Asia, Middle East, Africa and the Americas) Premaitha is free to be platform-agnostic providing tests for use on both Thermo Fisher and Illumina NGS platforms.
It should also be observed than compared to some stocks which have very much higher market capitalisations, Premaitha actually has a multitude of products already on the shelf.
The additional revenue streams above have yet to be included in the broker's revenue projections which pessimistically though DID include a softening of growth till the new CE-IVD. The unleashing of 80% opportunity referred (plus now free access to US, AUS, MEX) plus the additional products above apparently only provided 25% growth to £11.9m in the broker's forecast for 2021E. But I remain 'idealistic' that these revenue projections will be updated.
Despite these projections, which the Company has already distanced itself from, I note that in December 2016 Agilent Technologies bought Multiplicom for $72.8m. At the time Multiplicom had $6.5m sales so 11.2x EV/Sales. Hence suggesting that the current sp which is now heavily discounted.
On a side note there was an additional 400k shares bought this week at the placing price of 10p by an II separate to AR's additional 500k subscription. Given that Steve Myers passed the 8% threshold on the 23rd I suspect it was him. Hopefully we should recover to this placing price shortly and then mov
"We now have a new additional platform covering 80%...to sell our goods." Is that where now means 2020 lol I too think we are finally in the best position we have been in and now its up to the bod to prove worthy, free from litigation and deliver.
Lets put all this useless talk aside for a moment and concentrate on what we have in place already without the additional idealistic desires like Debt deal and Fincapp reassessment. We are at a point in time that is litigation free, money in the bank and an advancing business at a rate of very near 100% per year. Any debts we owe are covered by the warrants, and a good few years to go before the warrant period expires, and that only applies if TF declines the warrant offer. Confirmation from AR that expansion will be at a rapid rate and contracts will be acquired from missed litigation deterred opportunities alongside entirely new contracts formed from the newly evolved allegiance with Illumina. History has already shown us the speed at which new contracts can be acquired using only the TF platform, we now have a new additional platform covering 80% of the market place from which to sell our goods. With NIPT sales increasing exponentially and new products already making headway, our future could not look brighter. So please stop winging, moaning, badgering, crying or self deprecating. It really would sadden me to see heads in the basket of a do it yourself guillotine or willies hanging on a piece of string from a third floor window, yuk.
Patience is not only a virtue it's an essential part of the process, our time will come.
There was not some expected news I will give you that. Let's see whether this comes shortly.
I feel comfortable that with the annual report has already revealing the product route map, the Chairman already outlined how a wider planned strategy of debt forgiveness and warrant conversion with TMO, the CFO outlining the potential areas of geographical expansion pre and post Illumina CE-IVD development and the Vice Chairman the strategic opportunities now available to Premaitha as being a cross-platform molecular diagnostic firm; that the major elements of a new strategy have already been outlined. I would expect with the news of Company name change more elements would be revealed. I thought the AGM statement, aside from the potential trading update expected, was in keeping in style with last year's AGM statement.
A 6% share dilution has caused a 50% share value loss helped in no part to concerns over revenue forecasts (which the Company has already stated will be revised shortly following issue of a trading update); a brokers research notes (which the Company has already publicly distanced itself from and states will be updated probably by early November); and funding concerns (which the Chairman has already publicly addressed at the 16th presentation) and will in doubt comment further upon post the probable TMO debt forgiveness and warrant conversion exercise. Separate concerns raised about TMO strategic willingness to support the Company following the planned Illumina alliance have also been addressed via the probable TMO warrants conversion and the CEO's visit to the US to meet TMO. Your contribution in these discussions has also been duly noted.
It is fair to say that this 6% share dilution which has created a 50% share price loss has created a buying opportunity for some as progressively the concerns aired above have been responded to by the Company. With the Chairman buying further this week at 10p alongside Steve Myers I think we should gradually rise to the 10p placing floor level before long with the expected news flow of new reproductive product, trading update, revised broker forecast and potential TMO warrants. Hopefully this will allow us to move swiftly on from a fairly horrid few weeks.
All the best.
I remember your ironic remarks about the new CEO turning up to the AGM without a new strategy. How do you feel about it now? Strange we have had no reports back from the AGM. Did anyone go or was it just the directors?!
This is a perfect opportunity for some decent coms/pr from the company and some decent publicity for a change. It's the least the Bod could do after all of the recent fiascos, imo. How they manage the rebranding will be telling, and also indicative of where the Bod see this company going. Fingers crossed they get this right and we can look forward to a much healthier SP and return on our investment. A strong buy from me at current SP.